J&J Plans €1.75B Offer For Dutch Vaccine Developer

Law360, New York (September 20, 2010, 11:42 AM EDT) -- Johnson & Johnson is in advanced talks to buy the bulk of vaccine developer Crucell NV for €1.75 billion ($2.29 billion) through an all-cash public offer that would give the U.S. pharmaceutical giant full control over the Dutch company.

The potential deal, announced Friday, calls for J&J or a subsidiary to purchase all the Crucell shares it does not already own for €24.75 each. The company already owns about 17.9 percent of the Dutch company, valued at about €2.3 billion under the deal.

The negotiations, which...
To view the full article, register now.